-
Jan 29, 2025 | 
jwatch.org | Behnood Bikdeli
Behnood Bikdeli, MD, MS, reviewing Findings from an industry-sponsored, phase 2 trial of abelacimab suggest reduced bleeding compared with rivaroxaban. Although direct oral anticoagulants (DOACs) are effective anticoagulants for patients with atrial fibrillation (AF), bleeding events can be catastrophic or impair patient adherence.
-
Jan 8, 2025 | 
jwatch.org | Behnood Bikdeli
-
Nov 20, 2024 | 
jwatch.org | Behnood Bikdeli
Behnood Bikdeli, MD, MS, reviewing Among patients with low-risk pulmonary embolism, 18 months of anticoagulation significantly reduced its recurrence, compared with 6 months of treatment. Cancer is a well-known risk factor for incident and recurrent venous thromboembolism (VTE), including pulmonary embolism (PE). However, the optimal duration of anticoagulation in patients with cancer and low-risk PE is unknown.
-
Nov 2, 2024 | 
sciencedirect.com | Behnood Bikdeli |Harlan M. Krumholz
“Identification of hemodynamically stable patients with acute pulmonary embolism at high risk for death: external validation of different models”: comment • None Identification of hemodynamically stable patients with acute pulmonary embolism at high risk for death: external validation of different models • None Venous lactate improves the prediction of in-hospital adverse outcomes in normotensive pulmonary embolism • None Short-term clinical outcome of normotensive patients with acute PE and...
-
Sep 4, 2024 | 
jwatch.org | Behnood Bikdeli
-
Aug 28, 2024 | 
jwatch.org | Behnood Bikdeli
Behnood Bikdeli, MD, MS, reviewing In a small, open-label, randomized trial, risk for bleeding or thrombotic events was lower with low-intensity direct oral anticoagulants than with dual antiplatelet therapy. Left atrial appendage occlusion (LAAO) is a procedure performed most commonly in patients with atrial fibrillation, who have a high risk for subsequent bleeding from full-intensity anticoagulation.
-
Aug 14, 2024 | 
jwatch.org | Behnood Bikdeli
-
Jul 19, 2024 | 
jwatch.org | Behnood Bikdeli
Behnood Bikdeli, MD, MS, reviewing A clinical trial in the U.K. shows a significant reduction in hospital readmission. Whether telemonitoring confers benefit after hospital discharge in patients with acute coronary syndrome (ACS) is unclear. To examine this issue, researchers conducted an open-label trial among 337 patients with ACS who underwent percutaneous coronary intervention at a single institution.
-
Jul 8, 2024 | 
jwatch.org | Behnood Bikdeli
Behnood Bikdeli, MD, MS, reviewing Long-term follow-up of a clinical trial from China suggests a lower risk for major adverse cardiovascular events with dual antiplatelet therapy. A plethora of recent studies of patients with coronary disease suggests fewer ischemic and bleeding events with single antiplatelet monotherapy than with dual antiplatelet therapy (DAPT).
-
Jun 10, 2024 | 
jwatch.org | Behnood Bikdeli
Behnood Bikdeli, MD, MS, reviewing A subgroup analysis from the ARTESiA trial suggests that the CHA 2DS 2-VASc score can help with risk stratification. Several recent trials examine the benefits and risks of anticoagulation for atrial high-rate episodes (also known as silent atrial fibrillation [AF]; NEJM JW Cardiol Aug 30 2023 and N Engl J Med 2023; 389:1167; NEJM JW Cardiol Nov 13 2023 and N Engl J Med 2024; 390:107).
